Accueil   Lyonbiopole   Working groups GD€co   Thomas Kuhn

Thomas Kuhn

Poxel CEO


Thomas Kuhn is the Chief Executive Officer and a co-founder of Poxel. Thomas joined Merck KGaA in 2000, where he held various positions in clinical development, largely in the area of diabetes.


Between 2004 and 2007 he directed global R&D projects, with two products in Phase II clinical trials, and life cycle management projects, specifically for Glucophage®, the current reference in diabetes treatment. After the integration of Serono in 2007, Thomas was involved in refining Merck Serono's strategy.


With the decision to divest from diabetes as an integrated therapeutic area, Thomas drove the project to relocate the diabetes assets, leading to the establishment of Poxel. Thomas received a pharmacy degree from the University of Lyon I (France) and an MBA from Ashridge University (UK).

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close